Menu
X

Chinese Medicine Team Achieves Global Milestone: First Successful Treatment of Pancreatic Cancer Patient with Innovative Dual-Targeted CAR-T Cell Therapy (KD-496)!

🎉 Chinese Medicine Team Achieves Global Milestone: First Successful Treatment of Pancreatic Cancer Patient with Innovative Dual-Targeted CAR-T Cell Therapy (KD-496)!

Dual-Targeted CAR-T

Dual-Targeted CAR-T

 

Chinese Medicine

💪The team at the Department of Digestive Oncology, Peking University Cancer Hospital, led by Professor Shen Lin, has accomplished a groundbreaking feat! They have successfully completed the world’s first clinical study using an innovative dual-targeted CAR-T cell therapy (KD-496) for pancreatic cancer. This exciting news stems from their recent completion of the NCT06134960 study.

KD-496

⭐️This study, initiated by investigators (IIT), aims to evaluate the safety and efficacy of KD-496 CAR-T therapy for advanced NKG2DL+ /CLDN18.2+ solid tumors. It is a single-center, open-label, single-arm clinical study designed to explore the potential application of this new therapy in pancreatic cancer treatment.
 

CAR-T

⚡️On March 4, 2024, Professor Shen Lin’s team completed the infusion of KD-496 CAR-T cells for the first pancreatic cancer patient. The good news is that everything proceeded smoothly, with no adverse reactions reported in the participant, laying a solid foundation for the future application of this therapy.
 

NKG2DL+ /CLDN18.2+ solid tumors

🌤KD-496 CAR-T therapy targets advanced NKG2DL+ /CLDN18.2+ solid tumors, focusing primarily on pancreatic and gastric cancers, two urgent areas in digestive oncology. Currently, pancreatic cancer treatment primarily relies on surgery, but due to the lack of early symptoms, 80% of patients are often diagnosed at advanced stages, with a 5-year survival rate of less than 6%, necessitating urgent need for new treatment methods. On the other hand, despite advancements in gastric cancer treatment, the prognosis for advanced-stage patients remains bleak, with high incidence and mortality rates.
 

Hope

✨The success of Professor Shen Lin’s team marks a significant milestone in the medical field, offering new hope for patients with digestive system tumors. With the continued refinement and dissemination of this therapy, we hope to provide more effective treatment options for more patients, enabling them to regain new life. Let us look forward to future advancements, contributing to the development of medical technology and human health together!
 
🌈We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
🌦We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
 

WhatsApp+8613717959070

 
#ChineseMedicine #CancerTreatment #CART #PancreaticCancer #NewTherapy #Hope #ChineseMedicine #CARTCellTherapy #KD496 #PekingUniversityCancerHospital

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.